Vertex Pharmaceuticals is laying off workers and consolidating its real estate footprint in Rhode Island after ending a clinical program for Type 1 diabetes.

Vertex Pharmaceuticals is laying off 125 employees and consolidating their Rhode Island buildings after a failed diabetes treatment trial.

Fernando Jorge is a master of architectural silhouettes, crafting sleek and sensual jewellery that takes the curves of the body as its cue. Jorge, who works across a host of materials, from the ...

Vertex had plans to hire 1,300 employees in Wilmington, but it never even got close.

Vertex's pipeline is poised to produce other big winners. I don't just think Vertex is a stock to buy on the dip -- I think it's a screaming buy. Keith Speights has positions in Vertex ...

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped.

Is Vertex stock a buy? Vertex's share price is still in positive territory year to date despite today's pullback.

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Vertex Pharmaceuticals misses analyst estimates on the top and bottom lines in the first quarter. Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion ...

Google updated the documentation for the Google-Extended user agent, which publishers can use to control whether Google Gemini and Vertex use their data for training purposes or for grounding AI ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...